European Journal of Preventive Cardiology · 2023 · 57 citations · 23 references
MedicineCardiologyPreventive MedicineClinical CardiologyGeriatric AssessmentRisk AssessmentCardiac Risk AssessmentCardiovascular AssessmentCardiovascular DiseaseCardiovascular Disease PreventionCardiovascular RiskCoronary Artery DiseaseCardiovascular Risk StratificationClinical Utility AnalysisClinical Utility AssessmentCoronary Heart Disease Risk ScoresDiscrimination Of Risk ModelsIndependent Cohort ValidationIndependent ValidationRisk Score Validation
AIMS: The European Systematic Coronary Risk Evaluation 2 (SCORE2) and SCORE2-Older Persons (OP) models are recommended to identify individuals at high 10-year risk for cardiovascular disease (CVD). Independent validation and assessment of clinical utility is needed. This study aims to assess discrimination, calibration, and clinical utility of low-risk SCORE2 and SCORE2-OP. METHODS AND RESULTS: Validation in individuals aged 40-69 years (SCORE2) and 70-79 years (SCORE2-OP) without baseline CVD or diabetes from the European Prospective Investigation of Cancer (EPIC) Norfolk prospective population study. We compared 10-year CVD risk estimates with observed outcomes (cardiovascular mortality, non-fatal myocardial infarction, and stroke). For SCORE2, 19 560 individuals (57% women) had 10-year CVD risk estimates of 3.7% [95% confidence interval (CI) 3.6-3.7] vs. observed 3.8% (95% CI 3.6-4.1) [observed (O)/expected (E) ratio 1.0 (95% CI 1.0-1.1)]. The area under the curve (AUC) was 0.75 (95% CI 0.74-0.77), with underestimation of risk in men [O/E 1.4 (95% CI 1.3-1.6)] and overestimation in women [O/E 0.7 (95% CI 0.6-0.8)]. Decision curve analysis (DCA) showed clinical benefit. Systematic Coronary Risk Evaluation 2-Older Persons in 3113 individuals (58% women) predicted 10-year CVD events in 10.2% (95% CI 10.1-10.3) vs. observed 15.3% (95% CI 14.0-16.5) [O/E ratio 1.6 (95% CI 1.5-1.7)]. The AUC was 0.63 (95% CI 0.60-0.65) with underestimation of risk across sex and risk ranges. Decision curve analysis showed limited clinical benefit. CONCLUSION: In a UK population cohort, the SCORE2 low-risk model showed fair discrimination and calibration, with clinical benefit for preventive treatment initiation decisions. In contrast, in individuals aged 70-79 years, SCORE2-OP demonstrated poor discrimination, underestimated risk in both sexes, and limited clinical utility.
23
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Frank L.J. Visseren, François Mach, Yvo M. Smulders et al. · European Heart Journal · 2021 · 6.3K citations · Full text
Marlies Antlanger, Stefan Aschauer, Chantal Kopecky et al. · Kidney & Blood Pressure Research · 2017 · 2.8K citations · Full text